Well, we're not an industry voice, so if the industry thinks it's balanced, then I guess the public interest needs to ask if it's in the public interest. I would say no. We're paying too much for generic drugs and we're paying too much for brand-name drugs. The fact that they're both happy is not necessarily a good thing if you're concerned about a sustainable public health policy.
On January 28th, 2014. See this statement in context.